Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.42 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.42 |
| ▸ | ROCK1 known ✓ | Q13464 | 4/20 | 0.41 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.41 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.41 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.41 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.41 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29379635 | 1.00 | ALDH1A1 (0.44) | ALDH1A1LMNAACVR1BTGFBR1ACVR1 | |
| SCHEMBL521437 | 0.99 | ALDH1A1 (0.45) | ALDH1A1LMNAACVR1BTGFBR1ACVR1 | |
| SCHEMBL29851268 | 0.99 | ALDH1A1 (0.45) | ALDH1A1LMNAACVR1BTGFBR1ACVR1 | |
| SCHEMBL26087309 | 0.87 | ALDH1A1 (0.51) | ALDH1A1LMNASIRT6MAPTTDP1 | |
| SCHEMBL224959 | 0.84 | ALDH1A1 (0.46) | ALDH1A1LMNASIRT6MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL9014064 | 0.84 | MAPT (0.45) | ALDH1A1LMNAROCK1ROCK2PRKACA | |
| SCHEMBL25725927 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAROCK1ROCK2PRKACA | |
| SCHEMBL375364 | 0.82 | SIRT6 (0.57) | ALDH1A1LMNATGFBR1ACVR1SIRT6 | |
| SCHEMBL29446151 | 0.82 | SIRT6 (0.57) | ALDH1A1LMNATGFBR1ACVR1SIRT6 | |
| Hydrochloric Acid SCHEMBL29847893 | 0.82 | ATM (0.44) | ALDH1A1LMNAROCK1ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2024-12-24 | — | — | US | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-114042070-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-112004802-B | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-06-24 | — | — | US | disclosed |
| US-10968202-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2021-04-06 | — | — | US | disclosed |
| CN-112004802-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200369645-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-11-26 | — | — | US | disclosed |
| US-10730853-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2020-08-04 | — | — | US | disclosed |
| US-20200181112-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-06-11 | — | — | US | disclosed |
| US-10618886-B1 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2020-04-14 | — | — | US | disclosed |
| US-20200102289-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-04-02 | — | — | US | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102289-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | ACVR1 4373/4885KCNH2 969/4885ROCK1 1969/4885 |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ACVR1 4026/4885KCNH2 763/4885ROCK1 1846/4885 |
| US-20200181112-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-10618886-B1 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-10968202-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-20200369645-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
| US-10730853-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ACVR1 4222/4885KCNH2 499/4885ROCK1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.